Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Regulatory News (IMM)

Share Price Information for Immupharma (IMM)

Share Price is delayed by 15 minutes
Get Live Data
4.045    0.045 (1.13%)
Bid:
3.80
Ask:
4.295
Spread: 0.495 (13.026%)
Market Cap: £25.24m
IMM Live PriceLast checked at - London Stock Exchange

Intraday Immupharma Share Chart

Holding(s) in Company

16 Oct 2017 15:29

RNS Number : 7306T
Immupharma PLC
16 October 2017
Β 

TR-1: Standard form for notification of major holdings

Β 

Β 

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Immupharma Plc

213800VZKGHXC7VUS895

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

Β 

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

x

An acquisition or disposal of financial instruments

Β 

An event changing the breakdown of voting rights

Β 

Other (please specify)iii:

Β 

3. Details of person subject to the notification obligationiv

Name

Β 

Β 

Legal & General Group Plc (Group)

Β 

Β 

City and country of registered office (if applicable)

1 Coleman St, London EC2R 5AA

4. Full name of shareholder(s) (if different from 3.)v

Name

Β 

Legal & General Assurance Society (LGAS)

Β 

City and country of registered office (if applicable)

1 Coleman St, London EC2R 5AA

5. Date on which the threshold was crossed or reachedvi:

12 October 2017

6. Date on which issuer notified (DD/MM/YYYY):

Β 

16 October 2017

Β 

Β 

Β 

7. Total positions of person(s) subject to the notification obligation

Β 

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

Below 3%

-

Below 3%

132,522,985

Position of previous notification (if

applicable)

3.35%

-

3.35%

Β 

Β Β Β Β Β Β Β 

Β 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

ORD GBP 0.10

Below 3%

-

Below 3%

-

SUBTOTAL 8. A

Below 3%

Below 3%

Β 

Β 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

SUBTOTAL 8. B 1

Β 

Β 

Β 

Β 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

SUBTOTAL 8.B.2

Β 

Β 

Β 

Β Β Β Β Β Β Β Β Β Β 

Β 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Β 

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

x

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Β 

Legal & General Group (Direct/Indirect)

Below 5%

Β 

Below 5%

Β 

Legal & General Investment Management (Holdings) Limited

(Direct/Indirect)

Below 5%

Β 

Below 5%

Β 

Legal & General Assurance Society (Direct)

Below 3%

Β 

Below 3%

Β 

Β 

Β 

Β 

Legal & General Group (Direct/Indirect)

Below 5%

Β 

Below 5%

Legal & General Investment Management (Holdings) Limited

(Direct/Indirect)

Below 5%

Β 

Below 5%

Legal & General Assurance (Pensions Management) Limited

(Direct)

0%

Β 

0%

Β 

Β 

Β 

Β 

Legal & General Group (Direct/Indirect)

Below 5%

Β 

Below 5%

Legal & General Investment Management (Holdings) Limited

(Direct/Indirect)

Below 5%

Β 

Below 5%

Legal & General Investment Management Limited (Indirect)

Below 5%

Β 

Below 5%

Β 

Β 

Β 

Β 

Legal & General Group (Direct/Indirect)

Below 5%

Β 

Below 5%

Legal & General Investment Management (Holdings) Limited

(Direct/Indirect)

Below 5%

Β 

Below 5%

Legal & General (Unit Trust Managers) Limited (Indirect)

0%

Β 

0%

Β 

Β 

Β 

Β 

10. In case of proxy voting, please identify:

Name of the proxy holder

N/A

The number and % of voting rights held

N/A

The date until which the voting rights will be held

N/A

Β 

11. Additional informationxvi

Β 

Notification using the total voting rights figure of 132,522,985

Β 

Β Β Β Β Β 

Β 

Β 

Place of completion

Brunel House, 2 Fitzalan Road, Cardiff, CF24 0EB

Date of completion

16/10/2017

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
HOLZQLFFDBFLFBE
Date   Source Headline
25th Jun 20261:20 pmRNS2026 RESULT OF ANNUAL GENERAL MEETING
25th Jun 20267:00 amRNSImmuPharma appoints Bachem for Kapiglucagon API
24th Jun 20267:00 amRNS-RUniversity of Murcia research relating to P140
4th Jun 20267:10 amRNS-RIncanthera plc – Corporate Update & Board Changes
2nd Jun 20267:00 amRNSNotice of AGM & Annual Report & Accounts
27th May 20267:00 amRNSFinal Results
5th May 20267:00 amRNSIMM initiatesIND-Enabling Program for Kapiglucagon
10th Apr 20267:00 amRNSHolding(s) in Company
9th Apr 20267:00 amRNS-RChairman’s Open Letter to Shareholders
7th Apr 202611:45 amRNSResult of General Meeting and TVR
27th Mar 20267:00 amRNSP140 Program Update
23rd Mar 20267:00 amRNSResult of WRAP Retail Offer and TVR
19th Mar 20269:00 amRNSPublication of Circular
18th Mar 20267:00 amRNS-R‘Investor Meet Company’ presentation on 20 March
17th Mar 20267:01 amRNSWRAP Retail Offer for up to £1.5 million
17th Mar 20267:01 amRNSWRAP Retail Offer for up to £1.5 million
17th Mar 20267:00 amRNSP140 Update; Fundraise, Related Party Transaction
17th Mar 20267:00 amRNSP140 Update; Fundraise, Related Party Transaction
6th Jan 20264:11 pmRNSHolding(s) in Company
6th Jan 20267:00 amRNS-RAttending JPMorgan Conference & Biotech Showcase
24th Nov 20257:00 amRNSCorporate Update
4th Nov 20257:00 amRNSHolding(s) in Company
27th Oct 20257:00 amRNS-RIMMUPHARMA ATTENDING BIO-EUROPE
23rd Oct 20257:00 amRNSLaunch of Website; Corporate Update
13th Oct 20257:00 amRNSAppointment of Independent Non-Executive Director
6th Oct 20253:22 pmRNSHolding(s) in Company
17th Sep 20257:00 amRNSExercise of Warrants
11th Sep 20257:00 amRNSExercise of Warrants
1st Sep 20252:12 pmRNSAppointments of CSO and Head of R&D
1st Sep 20251:20 pmRNSImmuPharma Files New Patent Application for P140:
20th Aug 20251:36 pmRNSHolding(s) in Company
6th Aug 20257:00 amRNSInterim Results
12th Jun 202512:51 pmRNSResult of AGM
27th May 20253:13 pmRNSHolding(s) in Company
20th May 20257:00 amRNSNotice of AGM
19th May 20257:00 amRNSFinal Results
1st Apr 20257:00 amRNSWarrant Extension, Debt Conversion & Equity Issue
1st Apr 20257:00 amRNSExtension of Warrants in Incanthera to 30 Sep 2025
14th Mar 20257:00 amRNS-RIMM attending Bio-Europe Spring 17-19 March,Milan
13th Mar 20257:00 amRNSImmuPharma proves unique Mechanism of Action-P140
21st Feb 202511:36 amRNSHolding(s) in Company
13th Feb 20257:00 amRNS£2.91m fundraising; related party transactions
28th Jan 202512:57 pmRNSResponse to Share Price Movement
9th Jan 20257:00 amRNSBreakthrough Findings into Autoimmune Diseases
23rd Dec 20247:00 amRNSChange of Auditor
10th Dec 20242:36 pmRNSHolding(s) in Company
4th Dec 20247:00 amRNSAppointment of Company Secretary
9th Sep 20247:01 amRNSExtension of Warrants in Incanthera to 31 Mar 2025
9th Sep 20247:00 amRNSHalf-year Report
6th Aug 20241:41 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.